Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

被引:61
作者
Sadler, BM
Piliero, PJ
Preston, SL
Lloyd, PP
Lou, Y
Stein, DS
机构
[1] GlaxoSmithKline, Div Clin Pharmacol, Res Triangle Pk, NC 27709 USA
[2] Albany Med Coll, Div HIV Med, Albany, NY 12208 USA
[3] Albany Med Coll, Div Clin Pharmacol, Albany, NY 12208 USA
[4] Univ N Carolina, Sch Med, Chapel Hill, NC USA
关键词
protease inhibitors; amprenavir; ritonavir; safety; pharmacokinetics; drug interaction;
D O I
10.1097/00002030-200105250-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate the safely and pharmacokinetic interaction between amprenavir (APV) and ritonavir (RTV). Methods: Three open-label, randomized, two-sequence, multiple-dose studies having the same design (7 days of APV or RTV alone followed by 7 days of both drugs together) used 450 or 900 mg APV with 100 or 300 mg RTV every 12 h with pharmacokinetic assessments on days 7 and 14. Safety was monitored as clinical adverse events (AEs) and laboratory abnormalities. Results: Relative to APV alone, RTV co-administration resulted in a 3.3- to l-fold and 10.84 to 14.25-fold increase in the geometric least-square (GLS) mean area under the plasma concentration-time curve (AUC(tau .ss)) and minimum concentration (C-min,C-ss), respectively. APV 900 mg with RN 100 mg resulted in a 2.09-fold and 6.85-fold increase in the CLS mean AUC(tau ,ss) and C-min,C-ss, respectively. On day 14, the geometric mean (95% confidence interval) for 450 mg APV AUC(tau ,ss) (mug.h/mL) was 23.49 (19.32-28.57) with 300 mg RTV and 35.42 (30.46-44.42) with 100 mug RTV and for the 900 mg APV with 100 mg RTV 47.11 (39.47-61.24). The 450 mg APV C-min,C-ss (mug/ml) were 1.32 (1.05-1.67) and 2.01 (1.70-2.61), and 2.47 (2.08-3.32) for 900 mg APV. The most common AEs were mild and included diarrhea, nausea/vomiting, oral parasthesias, and rash. The triglyceride and cholesterol increased significantly from RTV exposure. Conclusion: Adding RTV to APV resulted in clinically and statistically significant increases in APV AUC and C-min with variable effects on maximum concentration. The two RTV doses had similar effects on APV but AEs were more frequent with 300 mg (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1009 / 1018
页数:10
相关论文
共 34 条
  • [1] Indinavir concentrations and antiviral effect
    Acosta, EP
    Henry, K
    Baken, L
    Page, LM
    Fletcher, CV
    [J]. PHARMACOTHERAPY, 1999, 19 (06): : 708 - 712
  • [2] *AG PHARM INC, 2001, VIR PROD INF PHYS DE
  • [3] BURGER DM, 1999, 39 INT C ANT AG CHEM
  • [4] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
    Carpenter, CCJ
    Cooper, DA
    Fischl, MA
    Gatell, JM
    Gazzard, BG
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schechter, M
    Schooley, RT
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03): : 381 - 390
  • [5] A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE
    DANNER, SA
    CARR, A
    LEONARD, JM
    LEHMAN, LM
    GUDIOL, F
    GONZALES, J
    RAVENTOS, A
    RUBIO, R
    BOUZA, E
    PINTADO, V
    AGUADO, AG
    DELOMAS, JG
    DELGADO, R
    BORLEFFS, JCC
    HSU, A
    VALDES, JM
    BOUCHER, CAB
    COOPER, DA
    GIMENO, C
    CLOTET, B
    TOR, J
    FERRER, E
    MARTINEZ, PL
    MORENO, S
    ZANCADA, G
    ALCAMI, J
    NORIEGA, AR
    PULIDO, F
    GLASSMAN, HN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) : 1528 - 1533
  • [6] Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
    Decker, CJ
    Laitinen, LM
    Bridson, GW
    Raybuck, SA
    Tung, RD
    Chaturvedi, PR
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (07) : 803 - 807
  • [7] DRUSANO G, 1997, 37 INT C ANT AG CHEM
  • [8] Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
    Fletcher, CV
    Brundage, RC
    Remmel, RP
    Page, LM
    Weller, D
    Calles, NR
    Simon, C
    Kline, MW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 1029 - 1034
  • [9] Pharmacologic considerations for therapeutic success with antiretroviral agents
    Fletcher, CV
    [J]. ANNALS OF PHARMACOTHERAPY, 1999, 33 (09) : 989 - 995
  • [10] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
    Gulick, RM
    Mellors, JW
    Havlir, D
    Eron, JJ
    Gonzalez, C
    McMahon, D
    Richman, DD
    Valentine, FT
    Jonas, L
    Meibohm, A
    Emini, EA
    Chodakewitz, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 734 - 739